Medacta Group SA Adjusts 2026 Guidance and Maintains Mid-term Outlook

Medacta Group SA has revised its financial outlook for 2026, now predicting a 9% revenue growth in constant currency, previously estimated between 10% and 14%. The adjusted EBITDA margin is expected to remain consistent with 2025 levels. This revision stems from softer conditions in the US healthcare market. Medacta had anticipated a market rebound in the latter half of 2026, which did not occur. Despite this, customer conversion rates in the US remain robust.

Medacta continues to project a revenue CAGR of 12% to 15% for the period 2024-2027, reaffirming confidence in the US market's future potential. The company emphasizes growth across its business lines, driven by its product portfolio and ongoing innovation. A conference call is scheduled for investors and analysts to discuss these updates.